What are Interferon beta-1a drugs?

Interferon beta-1a drugs are pharmacologic agents that share a common mechanism (typically targeting Type I interferon receptor (IFNAR)). 1 are currently marketed, with 2 more in clinical development.

What are the marketed Interferon beta-1a drugs?

Marketed Interferon beta-1a drugs include Rebif® (clone 484-39).

Interferon beta-1a

1 marketed 2 in Phase 3

This page covers all Interferon beta-1a drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting Type I interferon receptor (IFNAR), Interferon-beta receptor (IFNBR), Interferon-beta receptor (IFNAR).

Targets

Type I interferon receptor (IFNAR) · Interferon-beta receptor (IFNBR) · Interferon-beta receptor (IFNAR)

Marketed (1)

Rebif® (clone 484-39) · Merck KGaA, Darmstadt, Germany · Immunology / Neurology
Rebif is an interferon beta-1a that activates interferon receptors on immune cells to modulate immune response and reduce inflammation in the central nervous system.

Phase 3 pipeline (2)

Rebif New Formulation + prophylactic Ibuprofen · Merck KGaA, Darmstadt, Germany · Immunology / Neurology
Rebif (interferon beta-1a) activates interferon signaling pathways to modulate immune responses and reduce inflammation in the central nervous system, while prophylactic ibuprofen mitigates injection-site reactions and systemic inflammatory side effects.
Rebif New Formulation + ibuprofen PRN · Merck KGaA, Darmstadt, Germany · Immunology / Neurology
Rebif (interferon beta-1a) activates interferon signaling pathways to modulate immune responses and reduce inflammation in the central nervous system.